CN104383242A - Medicament composition for treating ovarian cyst and preparation method thereof - Google Patents
Medicament composition for treating ovarian cyst and preparation method thereof Download PDFInfo
- Publication number
- CN104383242A CN104383242A CN201410627856.1A CN201410627856A CN104383242A CN 104383242 A CN104383242 A CN 104383242A CN 201410627856 A CN201410627856 A CN 201410627856A CN 104383242 A CN104383242 A CN 104383242A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- preparation
- ovarian cyst
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention relates to a medicament composition for treating ovarian cyst and a preparation method thereof, belonging to traditional Chinese medicine technologies. Pharmacodynamic components of the medicament composition are prepared from the following components in parts by weight: 10-20 parts of motherwort herb, 10-20 parts of cassia twig, 10-20 parts of white atractylodes rhizome, 10-14 parts of dwarf lilyturf tuber, 5-15 parts of fingered citron, 4-8 parts of areca peel and 5-15 parts of bitter orange. The medicament composition disclosed by the invention has the effects of reinforcing qi and nourishing blood, promoting blood circulation and removing blood stasis, clearing heat and removing toxicity and resisting cancers, and can be used for effectively treating ovarian cyst, enhancing the appetite of patients and enhancing the immunity.
Description
[technical field]
The present invention relates to technical field of Chinese medicine, particularly a kind of pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof.
[technical background]
Ovarian cyst is gynecological clinic common disease, accounts for 90% of ovarian tumor.Be common in women at fertile age, sickness rate accounts for 5% of women at fertile age, ovarian cyst mostly is optimum, early stage many no conscious symptons, but along with the increase gradually of cyst, clinically there is the symptoms such as menstruation menstrual period, cycle irregular, dysmenorrhea, have a strong impact on health and the fertility of women, cause great misery to the body and mind of patient.It is closely related that modern medicine thinks that primary disease occurs with pelvic inflammatory disease recurrent exerbation, viral infection, endocrine disturbance etc.For the treatment of primary disease, under doctor trained in Western medicine often adopts antibiotic infection, operative treatment or B ultrasonic, localised puncture extracts capsule liquid, but there is easily recurrence, and Western medicine side effect is comparatively large, the problems such as Complications after surgical treatment is many.Chinese traditional treatment primary disease have accumulated rich experiences, satisfactory effect.But at present at the Chinese medicine having some treatment primary disease on the market, most onset is slow, uncertain therapeutic efficacy is cut and price is held high.Therefore, find a kind of safe and effective, taking convenience, low-cost Chinese medicine preparation become ovarian cyst patient in the urgent need to.
[summary of the invention]
The object of the present invention is to provide a kind of can pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof effectively, provided by the present invention be treatment ovarian cyst medicine can invigorating the spleen and benefiting QI, YIN nourishing is logical falls, ovarian cyst can be treated preferably, have no side effect, safe and reliable.
Technical scheme of the present invention is as follows:
A kind of pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, is characterized in that: the active ingredient of described pharmaceutical composition is prepared from by following raw material: Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae, Fructus Aurantii.
Further, the active ingredient of preferred described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 10 parts-20 parts, Ramulus Cinnamomi 10 parts-20 parts, the Rhizoma Atractylodis Macrocephalae 10 parts-20 parts, Radix Ophiopogonis 10 parts-14 parts, Fructus Citri Sarcodactylis 5 parts-15 parts, Pericarpium Arecae 4 parts-8 parts, Fructus Aurantii 5 parts-15 parts.
Further, the active ingredient of preferred described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 15 parts, Ramulus Cinnamomi 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Ophiopogonis 12 parts, Fructus Citri Sarcodactylis 10 parts, Pericarpium Arecae 6 parts, Fructus Aurantii 10 parts.
The dosage form of above-mentioned arbitrary pharmaceutical composition is preferably oral liquid, granule, capsule or tablet.
The preparation method of above-mentioned arbitrary pharmaceutical composition, is characterized in that, gets Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, add water 4-5 doubly by gross weight, and temperature fire decocts 2-3 hour, collecting decoction after decocting twice, filter, make oral liquid.
The preparation method of above-mentioned arbitrary pharmaceutical composition, is characterized in that, gets Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, adds water 4-5 doubly by gross weight, and temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters; Be concentrated into the paste that relative density is 1.32-1.40, then dry, pulverize into fine powder below 80 degree, add adjuvant, mixing, makes granule.
The preparation method of above-mentioned arbitrary pharmaceutical composition, is characterized in that, gets Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, adds water 4-5 doubly by gross weight, and temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters; Be concentrated into the paste that relative density is 1.32-1.40, then dry, pulverize into fine powder below 80 degree, add adjuvant, mixing, makes tablet.
The raw material of Chinese medicine medicine details adopted in the present invention is as follows:
Herba Leonuri, removing blood stasis, circulation of qi promoting, removing food stagnancy, pain relieving.Zhi lumps in the chest and abdomen, coagulation of QI-blood, trusted subordinate's pain, the lower swollen pain of the side of body, amenorrhea, postnatal blood stasis is suffered from abdominal pain, and traumatic injury, skin ulcer swells hard.
Ramulus Cinnamomi, sweet in the mouth, cold in nature.Return stomach, lung, large intestine, urinary bladder channel, heat-clearing and toxic substances removing, eliminating carbuncle eliminating stagnation, promoting urination to remove dampness.
The Rhizoma Atractylodis Macrocephalae, invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
Radix Ophiopogonis, cure mainly spitting of blood, spit blood, epistaxis, has blood in stool, metrorrhagia, traumatic hemorrhage, and breast ventral spine pain, tumbling down swells and ache.
Fructus Citri Sarcodactylis, has activating QI to eliminate phlegm, preventing or arresting vomiting relieving distension, the liver soothing and the spleen invigorating, the multiple medicinal function of stomach function regulating.
Pericarpium Arecae, has regulating qi-flowing for strengthening spleen, and in tune, dampness, reduces phlegm.Cure mainly distension and fullness in the abdomen or pain, the dyspepsia of stagnation of QI in spleen and stomach.The cough and asthma of the abdominal distention uncomfortable in chest in turbid damp resistance, indigestion and loss of appetite loose stool, phlegm-damp heap soil or fertilizer over and around the roots lung.
Fructus Aurantii, dispelling the stagnated QI, row expectorant, removing food stagnancy.Control chest and diaphragm expectorant stagnant, the feeling of stuffiness in chest, coerce swollen, food stagnation, eructation, vomiting, heavy after dysentery, proctoptosis, uterine prolapse.
The present invention adopts above technical scheme, compared with prior art, has the following advantages: effect that pharmaceutical composition tool benefiting QI and nourishing blood of the present invention, blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing are anticancer, effectively can treat ovarian cyst, strengthens patient's appetite, enhancing immunity.
Below in conjunction with detailed description of the invention, technical scheme of the present invention is described further.
[detailed description of the invention]
Embodiment 1
A kind of pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, is made up of (every part of 1g) according to weight classification following component: Herba Leonuri 10 parts, Ramulus Cinnamomi 10 parts of Rhizoma Atractylodis Macrocephalaes 10 parts, Radix Ophiopogonis 102 parts, Fructus Citri Sarcodactylis 5 parts of Pericarpium Arecae 4 parts, Fructus Aurantii 5 parts.
After above weight classification composition, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, adds adjuvant, make oral liquid.
Embodiment 2
A kind of pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, is made up of (every part of 1g) according to weight classification following component: Herba Leonuri 15 parts, Ramulus Cinnamomi 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Ophiopogonis 12 parts, Fructus Citri Sarcodactylis 10 parts, Pericarpium Arecae 6 parts, Fructus Aurantii 10 parts.
After above weight classification composition, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, be concentrated into the paste that relative density is 1.32-1.40, below 80 degree, dry, pulverize into fine powder again, add adjuvant (starch oar 10%, dextrin 10%, lactose 5%, dry starch 5%, stearic acid 2%, mannitol 1%, Talcum acid 2%), mixing, makes capsule.
Embodiment 3
A kind of pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, is made up of (every part of 1g) according to weight classification following component: Herba Leonuri 20 parts, Ramulus Cinnamomi 20 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Ophiopogonis 14 parts, Fructus Citri Sarcodactylis 15 parts, Pericarpium Arecae 8 parts, Fructus Aurantii 15 parts.
After above weight classification composition, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, be concentrated into the paste that relative density is 1.32-1.40, below 80 degree, dry, pulverize into fine powder again, add adjuvant (starch oar 10%, dextrin 10%, lactose 5%, dry starch 5%, stearic acid 2%, magnesium stearate 1%, Talcum acid 2%), mixing, makes granule.
Above three embodiment gained medicines are used for ovarian cyst clinical trial, and use efficacy assessment standard is:
1, effective: body constitution strengthens, limbs are strong, and hypogastralgia etc. are uncomfortable obviously to be alleviated, and CT examination ovary region tumors tumor body reduces, and other position does not find nascent tumor.
2, effective: body constitution strengthens, and the discomfort such as hypogastralgia, menoxenia has alleviation, and CT examination ovarian tumor tumor body has no increase, and other position has no nascent tumor.
3, worsen: disease is unchanged, and ovarian tumor tumor body increases to some extent, or other position finds nascent tumor.
The 80 routine ovarian cyst female patients of seeking medical advice year March in February, 2012 to 2014, age 20-85 year, the course of disease 3 months to 3 years.
This test is provided with 3 test group altogether, and each test group random assortment patient treats.Test group 1 use-case 1 gained Drug therapy, test group 2 uses the Drug therapy of embodiment 2 gained, and test group 3 uses the Drug therapy of embodiment 3 gained, if 20 examples are matched group, matched group adopts western medicine treatment, and total effective rate is 50%.
The result obtained is as following table:
| Test group | Number of cases | Effectively | Effective | Worsen | Effective percentage (%) |
| Test group 1 | 20 | 17 | 2 | 1 | 85％ |
| Test group 2 | 20 | 16 | 4 | 0 | 80％ |
| Test group 3 | 20 | 17 | 4 | 0 | 85％ |
| Matched group | 20 | 10 | 6 | 4 | 50％ |
From above data analysis, can draw the medicine of gained of the present invention treatment ovarian cyst, total effective rate reaches more than 80%, safe and reliable, have no side effect, and embodiment 3 is preferred plan, and effective percentage can reach 85%.
Although for reaching illustration purpose, the above is the preferred embodiments of the present invention, be not limited to the present invention, although with reference to previous embodiment to invention has been detailed description, for a person skilled in the art, it still can be modified to the technical scheme that foregoing embodiments is recorded, or carries out equivalent replacement to wherein portion of techniques feature.Within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by following raw material: Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae, Fructus Aurantii.
2. pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, it is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 10 parts-20 parts, Ramulus Cinnamomi 10 parts-20 parts, the Rhizoma Atractylodis Macrocephalae 10 parts-20 parts, Radix Ophiopogonis 10 parts-14 parts, Fructus Citri Sarcodactylis 5 parts-15 parts, Pericarpium Arecae 4 parts-8 parts, Fructus Aurantii 5 parts-15 parts.
3. pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof as claimed in claim 1, it is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 10 parts, Ramulus Cinnamomi 10 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Radix Ophiopogonis 10 parts, Fructus Citri Sarcodactylis 5 parts, Pericarpium Arecae 4 parts, Fructus Aurantii 5 parts.
4. pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof as claimed in claim 1, it is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 15 parts, Ramulus Cinnamomi 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Radix Ophiopogonis 12 parts, Fructus Citri Sarcodactylis 10 parts, Pericarpium Arecae 6 parts, Fructus Aurantii 10 parts.
5. pharmaceutical composition for the treatment of ovarian cyst and preparation method thereof, it is characterized in that, the active ingredient of described pharmaceutical composition is prepared from by the raw material of following weight portion: Herba Leonuri 20 parts, Ramulus Cinnamomi 20 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Ophiopogonis 14 parts, Fructus Citri Sarcodactylis 15 parts, Pericarpium Arecae 8 parts, Fructus Aurantii 15 parts.
6. pharmaceutical composition for the treatment of ovarian cyst as claimed in claim 1 and preparation method thereof, it is characterized in that, the dosage form of described pharmaceutical composition is oral liquid, granule, capsule or tablet.
7. pharmaceutical composition for the treatment of ovarian cyst as claimed in claim 1 and preparation method thereof, it is characterized in that, get Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, collecting decoction after decocting twice, filters, makes oral liquid.
8. pharmaceutical composition for the treatment of ovarian cyst as claimed in claim 1 and preparation method thereof, is characterized in that, get Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, be concentrated into the paste that relative density is 1.32-1.40, below 80 degree, dry, pulverize into fine powder again, add adjuvant, mixing, makes granule.
9. pharmaceutical composition for the treatment of ovarian cyst as claimed in claim 1 and preparation method thereof, is characterized in that, get Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, be concentrated into the paste that relative density is 1.32-1.40, below 80 degree, dry, pulverize into fine powder again, add adjuvant, mixing, makes tablet.
10. the pharmaceutical composition and preparation method thereof for the treatment of ovarian cyst as claimed in claim 1 or 2 or 3 or 4, is characterized in that, get Herba Leonuri, Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae, Radix Ophiopogonis, Fructus Citri Sarcodactylis, Pericarpium Arecae and Fructus Aurantii by weight ratio, add water 4-5 doubly by gross weight, temperature fire decocts 2-3 hour, and collecting decoction after decocting twice filters, be concentrated into the paste that relative density is 1.32-1.40, below 80 degree, dry, pulverize into fine powder again, add adjuvant, mixing, makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410627856.1A CN104383242A (en) | 2014-11-11 | 2014-11-11 | Medicament composition for treating ovarian cyst and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410627856.1A CN104383242A (en) | 2014-11-11 | 2014-11-11 | Medicament composition for treating ovarian cyst and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104383242A true CN104383242A (en) | 2015-03-04 |
Family
ID=52601266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410627856.1A Pending CN104383242A (en) | 2014-11-11 | 2014-11-11 | Medicament composition for treating ovarian cyst and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104383242A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105126040A (en) * | 2015-10-23 | 2015-12-09 | 戚炎月 | Medicine compound treating ovarian cysts and preparation method thereof |
| CN106138555A (en) * | 2015-04-13 | 2016-11-23 | 李湘 | A kind of pharmaceutical composition preventing premature ovarian failure and preparation method thereof |
| CN106138346A (en) * | 2015-04-13 | 2016-11-23 | 刘翠容 | A kind of pharmaceutical composition treating hysteromyoma and preparation method thereof |
-
2014
- 2014-11-11 CN CN201410627856.1A patent/CN104383242A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 杨医亚: "《中医学问答（上册）》", 28 February 1985, 人民卫生出版社 * |
| 田秋真等: ""肖承悰治疗卵巢囊肿经验"", 《河北中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138555A (en) * | 2015-04-13 | 2016-11-23 | 李湘 | A kind of pharmaceutical composition preventing premature ovarian failure and preparation method thereof |
| CN106138346A (en) * | 2015-04-13 | 2016-11-23 | 刘翠容 | A kind of pharmaceutical composition treating hysteromyoma and preparation method thereof |
| CN105126040A (en) * | 2015-10-23 | 2015-12-09 | 戚炎月 | Medicine compound treating ovarian cysts and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102151325B (en) | Traditional Chinese medicine for treating breast diseases | |
| CN101700393B (en) | Traditional Chinese medicine composition for treating breast cancer | |
| CN102824419B (en) | Traditional Chinese medicine composition for treating herpes zoster | |
| CN104288631A (en) | Medicine composition for treating colon cancer and preparation method thereof | |
| CN103920034A (en) | Traditional Chinese medicine composition for alleviating side effects of chemotherapy of cancer patient and preparation method traditional Chinese medicine composition | |
| CN103099993B (en) | Traditional Chinese medicine combination for treating uterine prolapse | |
| CN104383242A (en) | Medicament composition for treating ovarian cyst and preparation method thereof | |
| CN102579750B (en) | Traditional Chinese medicine composition for treating primary dysmenorrhea | |
| CN105326993A (en) | Traditional Chinese medicine composition for treating spermatorrhea and premature ejaculation | |
| CN104998232A (en) | Dysmenorrhea patch | |
| CN104666658A (en) | Traditional Chinese medicine composition for treating osteosarcoma ostalgia and bone metastasis neoplasm ostalgia, and preparation method and application of traditional Chinese medicine composition | |
| CN103655845A (en) | Traditional Chinese medicine composition for treating uterine prolapse | |
| CN104324091A (en) | Traditional Chinese medicine formula for treating rectal cancer | |
| CN101708266B (en) | Oral herbal decoction for treating osteoporosis | |
| CN105169279A (en) | Traditional Chinese medicine composition for treating knee joint bone hyperplasia | |
| CN106138555A (en) | A kind of pharmaceutical composition preventing premature ovarian failure and preparation method thereof | |
| CN102688453A (en) | Traditional Chinese medicine composite for treating breast cancer | |
| CN106138922A (en) | A kind of Chinese medicine formula treating rectal cancer | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN102836405B (en) | Medicament for treating encephaloma | |
| CN104873858A (en) | Traditional Chinese medicine composition for treating functional dysmenorrheal | |
| CN104666922A (en) | Chinese medicinal composition for treating irregular menstruation due to deficiency of qi in spleen and kidney | |
| CN106138346A (en) | A kind of pharmaceutical composition treating hysteromyoma and preparation method thereof | |
| CN105878871A (en) | Medicine composition for treating leukemia and preparation method thereof | |
| CN102178917B (en) | Chinese medicinal composition for treating qi channelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150304 |